MEDI 4736 (durvalumab) in non-small cell lung cancer.

Jeanson, Arnaud; Barlesi, Fabrice

Jeanson, Arnaud; Barlesi, Fabrice.

Affiliation

Jeanson A; a Aix Marseille University, Assistance Publique Hôpitaux de Marseille , Early Phase Cancer Center CLIP2 , Marseille , France.
Barlesi F; a Aix Marseille University, Assistance Publique Hôpitaux de Marseille , Early Phase Cancer Center CLIP2 , Marseille , France.

Expert Opin Biol Ther ; 17(10): 1317-1323, 2017 10.

Article in En | MEDLINE | ID: mdl-28705024

Subject(s)

Antibodies, Monoclonal/therapeutic use; Antineoplastic Agents/therapeutic use; Carcinoma, Non-Small-Cell Lung/drug therapy; Lung Neoplasms/drug therapy; Antibodies, Monoclonal/immunology; Antibodies, Monoclonal/pharmacokinetics; Antineoplastic Agents/metabolism; Antineoplastic Agents/pharmacokinetics; B7-H1 Antigen/immunology; Clinical Trials as Topic; Half-Life; Humans

Key words

PD-1; PD-L1; durvalumab; immune checkpoint inhibitors; non-small cell lung cancer

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms / Antibodies, Monoclonal / Antineoplastic Agents Type of study: Clinical_trials Limits: Humans Language: En Journal: Expert Opin Biol Ther Journal subject: BIOLOGIA / TERAPEUTICA Year: 2017 Type: Article Affiliation country: France

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google